Previous 10 | Next 10 |
Abiomed, Inc. (ABMD) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 ET Company Participants Ingrid Ward - Director, IR Michael Minogue - Chairman, CEO & President Todd Trapp - CFO & VP Conference Call Participants Danielle Antalffy - SVB Leerink Bruce Nudell...
The following slide deck was published by ABIOMED, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Eventbrite (NYSE: EB ) -34% on Q1 earnings . More news on: Eventbrite, Inc., VistaGen Therapeutics, Inc., ABIOMED, Inc., Stocks on the move, Read more ...
The FDA has signed off on a 668-subject clinical trial evaluating Abiomed's (NASDAQ: ABMD ) Impella CP heart pump in patients undergoing treatment for a type of heart attack called an ST-elevation myocardial infarction (STEMI). More news on: ABIOMED, Inc., Healthcare stocks news, Stock...
Abiomed ( ABMD ) Q4 results : Revenues: $207.1M (+18.8%). More news on: ABIOMED, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Abiomed (NASDAQ: ABMD ): Q4 GAAP EPS of $1.60 beats by $0.50 . More news on: ABIOMED, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial. The prospective, multi-center, two-arm trial plans to enroll 668 patients undergoing treatment for a ...
FY 2019 Annual Revenue of $769 Million, Up 30%, and 29.2% Operating Margin Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported fourth quarter fiscal 2019 revenue of $207.1 million, an increase of 19% compared to re...
Abiomed (NASDAQ: ABMD ) is a medical device company based in Danvers, Massachusetts specializing in heart pumps for a high risk heart surgery called Percutaneous Coronary Intervention ((PCI)). We believe the company's revolutionary Impella line of heart pump products will continue to revolutio...
New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's (NASDAQ: ABMD) Impella heart pumps during high-risk PCI (Protected PCI) enables skilled interventional cardiologists to achieve more complete revascularization, improved ejection fraction ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...